1. Home
  2. NNNN vs HAE Comparison

NNNN vs HAE Comparison

Compare NNNN & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNNN
  • HAE
  • Stock Information
  • Founded
  • NNNN 2021
  • HAE 1971
  • Country
  • NNNN Germany
  • HAE United States
  • Employees
  • NNNN N/A
  • HAE N/A
  • Industry
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • HAE Medical/Dental Instruments
  • Sector
  • NNNN Health Care
  • HAE Health Care
  • Exchange
  • NNNN Nasdaq
  • HAE Nasdaq
  • Market Cap
  • NNNN 2.2B
  • HAE 2.5B
  • IPO Year
  • NNNN 2025
  • HAE 1991
  • Fundamental
  • Price
  • NNNN $23.92
  • HAE $50.45
  • Analyst Decision
  • NNNN
  • HAE Buy
  • Analyst Count
  • NNNN 0
  • HAE 8
  • Target Price
  • NNNN N/A
  • HAE $76.88
  • AVG Volume (30 Days)
  • NNNN 76.5K
  • HAE 676.2K
  • Earning Date
  • NNNN 11-07-2025
  • HAE 11-06-2025
  • Dividend Yield
  • NNNN N/A
  • HAE N/A
  • EPS Growth
  • NNNN N/A
  • HAE 46.89
  • EPS
  • NNNN 0.06
  • HAE 3.28
  • Revenue
  • NNNN $8,185,146.00
  • HAE $1,346,046,000.00
  • Revenue This Year
  • NNNN N/A
  • HAE N/A
  • Revenue Next Year
  • NNNN N/A
  • HAE $6.42
  • P/E Ratio
  • NNNN $442.46
  • HAE $15.63
  • Revenue Growth
  • NNNN 21.95
  • HAE 0.91
  • 52 Week Low
  • NNNN $5.18
  • HAE $47.32
  • 52 Week High
  • NNNN $55.65
  • HAE $94.99
  • Technical
  • Relative Strength Index (RSI)
  • NNNN 35.64
  • HAE 46.89
  • Support Level
  • NNNN $26.05
  • HAE $50.30
  • Resistance Level
  • NNNN $30.65
  • HAE $52.09
  • Average True Range (ATR)
  • NNNN 2.72
  • HAE 1.28
  • MACD
  • NNNN -0.11
  • HAE 0.40
  • Stochastic Oscillator
  • NNNN 19.80
  • HAE 58.16

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: